WebDec 7, 2024 · A phase 3 trial, CLEAR Outcomes was designed as an event-driven, randomized, multicenter, double-blind, placebo-controlled trial with the aim of determining whether use of … WebJun 20, 2024 · The empagliflozin CVOT EMPA-REG OUTCOME was a pioneer study within the CVOT landscape, being among the first published, and the first to demonstrate cardioprotection. ... A clear pathway, with guidance on the place of each agent within it, would be a valuable support tool for endocrinologists, cardiologists, and primary care …
New players in the treatment of hypercholesterolaemia: focus on ...
WebSep 5, 2024 · The CVOT — known as CLEAR Cardiovascular Outcomes Trial — is an event-driven, global, randomized, double-blind, placebo-controlled study that completed enrollment in August 2024 in 14,032 patients with hypercholesterolemia and high CVD risk at over 1,400 sites in 32 countries. WebSep 5, 2024 · The CVOT — known as CLEAR Cardiovascular Outcomes Trial — is an event-driven, global, randomized, double-blind, placebo-controlled study that completed enrollment in August 2024 in 14,032... godfathers coupons omaha
Clear Outcomes Faculty of Nursing - University of Alberta
WebMar 16, 2024 · The primary outcome was a composite of progression of kidney disease and death from CV causes, with kidney disease progression being defined as kidney failure, sustained decrease in eGFR to < 10 mL/min/1.73 m 2, sustained decrease in eGFR of ≥ 40% from baseline, or kidney death. WebDec 15, 2016 · Primary Outcome Measures : Time from randomization to first occurrence of one of the following adjudicated composite endpoints: CV death, nonfatal myocardial … WebCurrent Weather. 11:19 AM. 47° F. RealFeel® 40°. RealFeel Shade™ 38°. Air Quality Excellent. Wind ENE 10 mph. Wind Gusts 15 mph. bony bridging radiology